CEX Capital joins PlusQuam Pharma as a strategic partner to drive its growth in the pharmaceutical sector

This signing ratifies the agreement adopted last January by the Corporation’s Board of Directors to acquire a 25% stake in the company, within the framework of its strategic support model for businesses with growth potential, innovation capacity, and the ability to generate added value in Extremadura.

PLUSQUAM PHARMA is the only pharmaceutical company of its kind headquartered in Extremadura and operates in the Pharma and Consumer Health sectors, focusing on four product areas: urological health, comprehensive women’s health, digestive probiotics, and functional oral rehydration, through brands such as UROCRAN, ACTIFEMME, VITAPLUS, and HIDRASAL. Among them, UROCRAN has established itself as a leading national brand within its segment.

An innovative company with growth potential

As highlighted by CEX Capital’s Investment Director, Eduardo Rodríguez Quirós, “PLUSQUAM PHARMA represents the type of business project we aim to support at the Corporation: an innovative company with specialized expertise, growth potential, and a strong commitment to health, research, and development from Extremadura.”

Rodríguez Quirós also emphasized that “the pharmaceutical and healthcare sector is strategic for regional economic development due to its ability to generate skilled employment, innovation, and high value-added business activity.”

For her part, María Romero, CEO of PLUSQUAM PHARMA, stated that “CEX Capital’s incorporation represents strategic backing for the company’s project and our sustainable growth model. We share a long-term vision that will allow us to strengthen our commercial and innovation capabilities in order to continue developing solutions aimed at improving people’s quality of life.”

PLUSQUAM PHARMA began operations in 2011 and is led by pharmaceutical partners with extensive experience in the pharmaceutical industry, developing food supplements, medical devices, and cosmetic products under the highest European quality standards.

CEX Capital’s commitment to accelerate growth

Since its inception, the company has maintained a strategy based on continuous innovation and the development of solutions designed to improve people’s quality of life, supported by an R&D&I department made up of pharmacists, mathematicians, and physicians.

The objective of CEX Capital’s investment is to accelerate the company’s growth through new investments in commercial operations, marketing, and R&D&I, while expanding its product portfolio and strengthening its market positioning.

As the Corporation notes, CEX Capital’s model is based on supporting companies during their expansion and consolidation phases, participating as a strategic partner to foster growth and strengthen Extremadura’s business ecosystem.

About PLUSQUAM PHARMA

PLUSQUAM PHARMA is a pharmaceutical company specialized in the development of food supplements, medical devices, and cosmetic products, operating in the areas of urological health, women’s health, digestive probiotics, and functional oral rehydration. The company develops science-based solutions aimed at preventing health issues and improving people’s quality of life by combining research, innovation, and specialization.

About CEX Capital

CEX Capital (Corporación Empresarial de Extremadura) is an investment company focused on regional development, established in 1992 under the auspices of the Spanish Royal Household. Since its creation, CEX Capital has participated in more than 60 business operations in the region, mobilizing over €1 billion in induced investment and generating more than 5,500 direct jobs.

The Corporation has a unique investment and strategic support model in Spain, backed by a strong shareholder base composed of major business groups, financial institutions, the Regional Government of Extremadura, and leading regional and national companies.